ES392074A1 - Un procedimiento para preparar compuestos de clatrato de prostaglandinas. - Google Patents

Un procedimiento para preparar compuestos de clatrato de prostaglandinas.

Info

Publication number
ES392074A1
ES392074A1 ES392074A ES392074A ES392074A1 ES 392074 A1 ES392074 A1 ES 392074A1 ES 392074 A ES392074 A ES 392074A ES 392074 A ES392074 A ES 392074A ES 392074 A1 ES392074 A1 ES 392074A1
Authority
ES
Spain
Prior art keywords
group
carbon atoms
formula
cyclodextrin
see formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES392074A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of ES392074A1 publication Critical patent/ES392074A1/es
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES392074A 1970-06-10 1971-06-09 Un procedimiento para preparar compuestos de clatrato de prostaglandinas. Expired ES392074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP45050119A JPS503362B1 (es) 1970-06-10 1970-06-10

Publications (1)

Publication Number Publication Date
ES392074A1 true ES392074A1 (es) 1974-08-01

Family

ID=12850213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES392074A Expired ES392074A1 (es) 1970-06-10 1971-06-09 Un procedimiento para preparar compuestos de clatrato de prostaglandinas.

Country Status (22)

Country Link
US (1) US3816393A (es)
JP (1) JPS503362B1 (es)
AT (1) AT332570B (es)
BE (1) BE768288A (es)
CA (1) CA958007A (es)
CH (1) CH568259A5 (es)
CS (1) CS170169B2 (es)
CY (1) CY895A (es)
DE (1) DE2128674C2 (es)
DK (1) DK140837B (es)
ES (1) ES392074A1 (es)
FR (1) FR2100745B1 (es)
GB (1) GB1351238A (es)
HK (1) HK17577A (es)
HU (1) HU163135B (es)
IE (1) IE35326B1 (es)
NL (1) NL162901C (es)
NO (1) NO134373C (es)
RO (1) RO62182A (es)
SE (1) SE390818B (es)
SU (1) SU404225A3 (es)
ZA (1) ZA713398B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163108A (en) * 1967-02-16 1979-07-31 Lever Brothers Company Prostaglandins
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
US3954833A (en) * 1971-04-12 1976-05-04 The Upjohn Company 16,16-Methyl and ethyl substituted PGF2.sub.α compounds
CA984387A (en) * 1971-04-12 1976-02-24 Barney J. Magerlein Analogs of prostaglandins
US3903131A (en) * 1971-04-12 1975-09-02 Upjohn Co 16 and 16,16-dimethyl PGE{HD 2{B
FR2134673A1 (en) * 1971-04-30 1972-12-08 Ono Pharmaceutical Co Novel optically active isomers of prostaglandin analoguesof natural configuration useful as hypotensive agents, diuretics,contraceptives, for treating gastric ulcer and asthma, and forinhibiting platelet aggregation
US4045467A (en) * 1972-02-18 1977-08-30 May & Baker Limited Cyclopentane derivatives
US4082789A (en) * 1972-03-28 1978-04-04 The University Court Of The University Of Edinburgh Prostaglandins C2
JPS4926258A (es) * 1972-07-06 1974-03-08
US4130721A (en) * 1972-07-24 1978-12-19 The Upjohn Company 11-Deoxy PGE2 compounds
US4110368A (en) * 1972-07-24 1978-08-29 American Cyanamid Company Hydro substituted prostanoic acids and esters
US4141914A (en) * 1972-07-24 1979-02-27 American Cyanamid Company Novel 11-deoxy-11-substituted prostaglandins of the E and F series
JPS4942648A (es) * 1972-08-24 1974-04-22
US3962312A (en) * 1972-09-21 1976-06-08 Ono Pharmaceutical Company 9,11,15-Trihydroxy prost-5-enoic acid analogues
US3972917A (en) * 1972-10-27 1976-08-03 American Home Products Corporation 11-Deoxy 15-methyl prostaglandin E1
JPS5443570B2 (es) * 1972-10-27 1979-12-20
US4092427A (en) * 1973-04-16 1978-05-30 American Home Products Corporation Method of inducing abortion using alkyl derivatives of prostanoic acids
JPS5623984B2 (es) * 1973-04-19 1981-06-03
US4246426A (en) * 1973-08-06 1981-01-20 Hoffmann-La Roche Inc. 11-Substituted prostaglandins
US4059576A (en) * 1973-08-06 1977-11-22 Hoffmann-La Roche, Inc. 11-Substituted prostaglandins
US4052446A (en) * 1973-08-06 1977-10-04 Hoffmann-La Roche Inc. 11,16-substituted prostaglandins
US4026927A (en) * 1973-09-25 1977-05-31 Yamanouchi Pharmaceutical Co., Ltd. Novel prostaglandin derivatives
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
GB1448268A (en) * 1973-11-13 1976-09-02 May & Baker Ltd Cyclopentane derivatives
GB1441564A (en) * 1974-02-07 1976-07-07 Upjohn Co Prostaglandins
US4041066A (en) * 1974-02-07 1977-08-09 The Upjohn Company 4,5-Cis-didehydro-PGE1 compounds
DE2416193C2 (de) * 1974-04-03 1985-08-14 Hoechst Ag, 6230 Frankfurt Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
US4256651A (en) * 1974-10-02 1981-03-17 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF1β compounds
US3974195A (en) * 1974-10-02 1976-08-10 The Upjohn Company 2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
GB1482010A (en) * 1974-10-28 1977-08-03 Ono Pharmaceutical Co Prostaglandin analogues
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4207420A (en) * 1975-02-24 1980-06-10 The Upjohn Company 2,2-Difluoro-PGF1 analogs
US4209637A (en) * 1975-02-24 1980-06-24 The Upjohn Company 2,2-Difluoro-PGF2 analogs
US4059701A (en) * 1975-04-17 1977-11-22 American Home Products Corporation 15-Substituted prostanoic acids for treating bronchial spasm
FR2313019A2 (fr) * 1975-06-04 1976-12-31 Ono Pharmaceutical Co Nouveaux analogues de prostaglandines et leur procede de preparation
US4086269A (en) * 1975-07-07 1978-04-25 American Home Products Corporation 11-Deoxy-15-substituted prostaglandins
US4026909A (en) * 1975-07-14 1977-05-31 The Upjohn Company Cis-13-PGF2.sub.α analogs
US4016184A (en) * 1975-09-17 1977-04-05 The Upjohn Company 9-Deoxy-9,10-didehydro-PGD1 compounds
US4033989A (en) * 1975-09-17 1977-07-05 The Upjohn Company 9-Deoxy-PGF2 Analogs
US4013695A (en) * 1975-10-02 1977-03-22 The Upjohn Company 4,4,5,5-Tetradehydro-PGE1 analogs
US4053500A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGF1α analogs
US4053502A (en) * 1975-10-02 1977-10-11 The Upjohn Company 4,4,5,5-Tetradehydro-ω-aryl-PGE1 analogs
US4026919A (en) * 1975-10-23 1977-05-31 The Upjohn Company PGD2 Substituted esters
US4058665A (en) * 1975-11-06 1977-11-15 Yamanouchi Pharmaceutical Co., Ltd. Novel 3,15-dilower alkyl PGE2 derivatives
US4212986A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE2 analogs
US4212987A (en) * 1976-09-17 1980-07-15 The Upjohn Company 2,2-Difluoro-PGE1 analogs
US4169895A (en) * 1976-09-28 1979-10-02 Pfizer Inc. Antisecretory 16,16-dimethyl-17-oxaprostaglandins
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU179141B (es) * 1977-09-23 1982-08-28
JPS5577440U (es) * 1978-11-25 1980-05-28
US4244883A (en) * 1979-09-12 1981-01-13 The Upjohn Company 2a,2b-Dihomo-15-alkyl-PGF2β compounds
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE3608088C2 (de) * 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
PT89301B (pt) * 1987-12-22 1995-07-03 Glaxo Group Ltd Processo para a preparacao de composicoes aquosas que contem um derivado do acido piperridinil-ciclo-pentil-heptenoico
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
DE19828881A1 (de) * 1998-06-22 1999-12-23 Schering Ag Oxidationsinhibitor bei Prostan-Derivaten
US6287603B1 (en) 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
MXPA04000757A (es) 2001-07-23 2004-07-08 Ono Pharmaceutical Co Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
US20070270489A1 (en) 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
CN100542537C (zh) * 2004-07-27 2009-09-23 中国人民解放军军事医学科学院毒物药物研究所 前列腺素e1口腔制剂
WO2006137959A1 (en) * 2005-06-13 2006-12-28 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
CN101223182A (zh) * 2005-06-13 2008-07-16 嘉吉公司 环糊精包合复合物及其制备方法
WO2007145663A1 (en) * 2006-06-13 2007-12-21 Cargill, Incorporated Large-particle cyclodextrin inclusion complexes and methods of preparing same
US20100160623A1 (en) * 2006-12-27 2010-06-24 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
MX2009008606A (es) 2007-02-16 2009-09-16 Ono Pharmaceutical Co Agente terapeutico para trastorno de excrecion urinaria.
KR20100016299A (ko) 2007-05-08 2010-02-12 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 Ep4 아고니스트를 함유하여 이루어지는 세포 상해성 t 세포의 활성화제
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
DK2441760T3 (en) 2009-06-10 2014-02-17 Ono Pharmaceutical Co A compound of bladder muscle contraction activity and activity urinrørsmuskelafslappende
JP4890657B1 (ja) * 2011-06-03 2012-03-07 小野薬品工業株式会社 リマプロストとβ−シクロデキストリンを含有する錠剤
SG2014007603A (en) 2011-08-02 2014-03-28 Ono Pharmaceutical Co Left ventricular diastolic function improving agent
SG11201501451SA (en) 2012-08-31 2015-04-29 Ono Pharmaceutical Co Amine salt and crystals thereof
PT3456710T (pt) 2016-05-09 2021-09-02 Agc Inc Novo derivado de prostaglandina
WO2023037934A1 (ja) * 2021-09-13 2023-03-16 富士フイルム株式会社 ビシクロアルカン化合物の包摂体の製造方法

Also Published As

Publication number Publication date
FR2100745B1 (es) 1974-08-30
CH568259A5 (es) 1975-10-31
DE2128674A1 (de) 1971-12-16
NL162901B (nl) 1980-02-15
ATA480371A (de) 1976-01-15
NO134373B (es) 1976-06-21
HU163135B (es) 1973-06-28
US3816393A (en) 1974-06-11
FR2100745A1 (es) 1972-03-24
HK17577A (en) 1977-04-22
CA958007A (en) 1974-11-19
IE35326B1 (en) 1976-01-07
SU404225A3 (es) 1973-10-26
GB1351238A (en) 1974-04-24
DK140837C (es) 1981-09-07
BE768288A (fr) 1971-11-03
RO62182A (es) 1977-07-15
ZA713398B (en) 1972-01-26
AT332570B (de) 1976-10-11
DE2128674C2 (de) 1982-06-24
JPS503362B1 (es) 1975-02-04
NL7107894A (es) 1971-12-14
NO134373C (es) 1976-09-29
CY895A (en) 1977-10-07
CS170169B2 (es) 1976-08-27
IE35326L (en) 1971-12-10
NL162901C (nl) 1980-07-15
SE390818B (sv) 1977-01-24
DK140837B (da) 1979-11-26

Similar Documents

Publication Publication Date Title
ES392074A1 (es) Un procedimiento para preparar compuestos de clatrato de prostaglandinas.
GB1492276A (en) Production of ethers
GB1511339A (en) Electronic musical instruments
ES433437A1 (es) Procedimiento para la preparacion de beta-aminosilanos y beta-aminosiloxanos.
ES436613A1 (es) Un procedimiento para la preparacion de una composicion far-maceutica estabilizada.
ES477364A1 (es) Un proceso para producir un ester glicolipido hidroxialqui- loeterificado.
ES397726A1 (es) Un procedimiento para la preparacion de derivados de iononay de irona.
ES402608A1 (es) Procedimiento para el desdoblamiento de racematos de d, 1- fenilpropanolamina con acidos opticamente activos.
ES429020A1 (es) Procedimiento para preparar nuevos derivados de tiazol-5- metanol.
GB1139860A (en) Cyclic ethers of cardenolide digitoxosides
ES440282A1 (es) Procedimiento para la preparacion de piperidina.
GB1449882A (en) Prostaglandin analogues
ES399182A1 (es) Procedimiento para la preparacion de beta-alquiltio-aldehi-dos.
ES402328A1 (es) Procedimiento para preparar 4-hidroxibenzodio-xol.
ES391177A1 (es) Procedimiento para la preparacion de compuestos de acetile-no con efecto fungistatico y bacteriostatico.
ES394504A1 (es) Un procedimiento para la preparacion de compuestos trici- clicos.
ES441003A1 (es) Un procedimiento para preparar productos intermedios utiles en la sintesis de prosglandinas.
ES401515A1 (es) Procedimiento para la obtencion de eteres sililicos este- roidales.
ES325263A1 (es) Procedimiento para la produccion de esteroides
ES283494A1 (es) Procedimiento de preparación de compuestos de acciones terapéuticas
ZA74295B (en) Clathrate compounds of prostaglandins or their analogues with cyclodextrin
ES438446A1 (es) Procedimiento de preparacion de nuevos compuestos espirohe- terociclanicos.
GB773628A (en) Steroids
ES437041A1 (es) Un procedimiento para preparar derivados de 1-ftalazona.
GB773928A (en) Steroids